CJC-1295 vs Copper Tripeptide-1
Side-by-Side Comparison
| Attribute | Cjc 1295 | Copper Tripeptide 1 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Cosmetic Peptide |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | GHK-Cu delivers copper ions to skin cells while the GHK peptide acts as a signaling molecule. Copper is a cofactor for lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant... |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Not approved for human use | Cosmetic ingredient with clinical studies. Also studied for wound healing. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well tolerated topically; Mild irritation possible at higher concentrations |
| Route | Subcutaneous | Topical |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | Serums containing 0.5–2% copper tripeptide-1 (GHK-Cu) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 1–2 times daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | N/A |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | N/A |
Overview
CJC-1295 and Copper Tripeptide-1 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Copper Tripeptide-1 — Mechanism & Evidence
Copper tripeptide-1 (GHK-Cu) is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Note: This entry focuses on the cosmetic/dermatological use of GHK-Cu. For comprehensive coverage of GHK-Cu as a wound healing and research peptide, see the dedicated GHK-Cu entry. Copper tripeptide-1 is used extensively in anti-aging skincare and hair care products. It has demonstrated wound healing, collagen-stimulating, and anti-inflammatory properties in published studies. Among cosmetic peptides, GHK-Cu has a relatively strong evidence base, including several controlled clinical studies.
Key claims: Stimulates collagen synthesis and improves skin firmness; Promotes wound healing; Reduces photodamage signs.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while Copper Tripeptide-1 targets Anti-Aging Skincare, Wound Healing.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Copper Tripeptide-1: Generally well tolerated topically Mild irritation possible at higher concentrations Rare allergic contact dermatitis
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.